In a report released today, Louise Chen from Cantor Fitzgerald maintained a Hold rating on Endo International (ENDP), with a price target of $18. The company’s shares opened today at $12.61.
Chen noted:
“We rate ENDP as 12-month price target of $18. We think the risk reward for ENDP’s existing business and new opportunities is already accurately reflected in its stock price. Better-than-expected Phase 3 data for CCH, a pick up in ENDP’s generics business and/or lower-than-expected calls on ENDP’s cash (debt, testosterone) would make us more positive on the stock. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $18.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 10.2% and a 40.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Endo International with a $17.94 average price target, implying a 42.3% upside from current levels. In a report issued on November 8, Cowen & Co. also maintained a Hold rating on the stock with a $9 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.50 and a one-year low of $5.27. Currently, Endo International has an average volume of 4.3M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals.
